Strain of bacillus licheniformis for degrading arginine and use thereof

By developing a Bacillus licheniformis that degrades arginine, prepared as a drug or health care product, the shortcomings of hyperarginemia treatment were solved, and the effect of significantly reducing arginine levels was achieved, with the treatment and prevention of high levels. The potential of arginemia.

WO2024234552A1PCT designated stage expired Publication Date: 2024-11-21SUZHOU U-SYNBIO TECHNOLOGIES CO LTD
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2023/125918
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-18
Filing Date
2023-10-23
Publication Date
2024-11-21

AI Technical Summary

Technical Problem

Currently, there is a lack of effective safe and non-toxic treatments for hyperarginemia. The existing treatment mainly relies on dietary control and drug treatment. There is no consensus cure. Early diagnosis is crucial to avoid irreversible neurological damage. .

Method used

A strain of Bacillus licheniformis, which degrades arginine, was developed as a medicine or health product prepared by bacterial agents to reduce arginine levels, for the treatment and prevention of hyperarginemia, including the use of lichen spores Bacillus inoculation and culture, liquid or solid bacteria agents are prepared, and administered in the form of casing preparations.

Benefits of technology

Bacillus licheniformis significantly reduced arginine levels and had the therapeutic potential to alleviate hyperarginemia. Its ability to degrade arginine through in vitro and animal experiments can effectively slow down and control the progress of the disease.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN2023125918_21112024_PF_FP_ABST
    Figure CN2023125918_21112024_PF_FP_ABST
Patent Text Reader

Abstract

Disclosed in the present invention are a strain of Bacillus licheniformis for degrading arginine and the use thereof. The Bacillus licheniformis provided in the present invention has been deposited in the China General Microbiological Culture Collection Center on April 14, 2013, with the deposition address of No. 3, Yard No. 1, Beicheng West Road, Chaoyang District, Beijing, and the deposition number of CGMCC No. 27112. The Bacillus licheniformis provided in the present invention can significantly reduce the level of arginine, has the potential of relieving hyperarginemia, and can be used for preparing a drug or a health care product for the treatment and / or prevention of hyperarginemia.
Need to check novelty before this filing date? Find Prior Art

Description

Arginine-degrading Bacillus licheniformis and its application Technical Field

[0001] The invention relates to a strain of Bacillus licheniformis capable of degrading arginine and application thereof, belonging to the technical field of microorganisms. Background Art

[0002] Arginine (Arg) is a nutritionally semi-essential, proteinogenic amino acid involved in multiple pathways and physiological processes. Arginine is primarily derived from three sources in the body: dietary intake, endogenous synthesis, and conversion to endogenous proteins. Hyperargininemia is an autosomal recessive genetic disorder caused by a deficiency in arginase-1 in the urea cycle, characterized by abnormally elevated blood arginine levels.

[0003] Hyperargininemia is generally difficult to cure, but early detection and treatment can effectively control its progression. If clinical symptoms are not detected promptly, severe and irreversible neurological damage may already be present at diagnosis, leading to progressive and potentially life-threatening conditions. Hyperargininemia symptoms can be effectively controlled and improved through dietary and medication therapy. Dietary therapy is the key treatment modality. Due to arginase deficiency, daily arginine and protein intake can be restricted, ensuring energy supply through carbohydrate and fat intake. A low-arginine diet is essential to reduce nitrogen intake and metabolism. Dietary therapy maintains normal blood arginine levels, slowing and preventing the progressive development of the disease and preventing the development of severe, irreversible neurological symptoms. In addition to dietary therapy, dialysis can be used to rapidly reduce blood ammonia levels in the event of acute hyperammonemia. Anticonvulsants, such as common medications like phenobarbital and carbamazepine, can be administered if seizures occur. Intravenous or oral nitrogen scavengers, such as sodium benzoate and sodium phenylbutyrate, can also be considered for denitrification therapy to promote the excretion of endogenous ammonia in the urine. Other options, such as liver transplantation, stem cell transplantation, and gene therapy, are still under investigation.

[0004] The composition and function of intestinal flora play an important role in the occurrence and development of many metabolic diseases. It has gradually become a new target for disease prevention and treatment, and a series of probiotics have been developed. Probiotics have undergone years of development and exploration from the laboratory research stage to clinical application. The species and mechanism of action of probiotics have gradually become clear, and their clinical application has become more and more extensive. Because the pathogenesis of hyperargininemia is not yet fully understood, although clinical treatment has made certain progress, it is still at the stage of controlling or alleviating symptoms, and there is no consensus on safe and effective treatment or cure. Therefore, there is an urgent need in this field to develop an effective new, non-toxic and side-effect-free drug for the prevention and treatment of hyperargininemia and its related diseases.

[0005] Summary of the Invention

[0006] To solve the above technical problems, the present invention provides a strain of Bacillus licheniformis that degrades arginine and its application. The Bacillus licheniformis can significantly reduce arginine levels, has the therapeutic potential to alleviate hyperargininemia, and can be used to prepare medicines or health products for treating and / or preventing hyperargininemia.

[0007] The first object of the present invention is to provide a strain of Bacillus licheniformis that degrades arginine. The Bacillus licheniformis is taxonomically named Bacillus licheniformis, which was deposited in the General Microbiology Center of the China Culture Collection Administration on April 14, 2023, with a deposit number of CGMCC No. 27112, and the deposit address is No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing.

[0008] The second object of the present invention is to provide a bacterial agent containing the Bacillus licheniformis.

[0009] Furthermore, the bacterial agent is prepared by the following method:

[0010] The Bacillus licheniformis strain is inoculated into a culture medium for cultivation, the bacterial bodies are collected after cultivation, and the collected bacterial bodies are prepared into the bacterial agent.

[0011] Furthermore, the bacterial agent is a liquid bacterial agent or a solid bacterial agent.

[0012] The third object of the present invention is to provide the use of the Bacillus licheniformis or the bacterial agent in the preparation of medicines or health products for treating and / or preventing hyperargininemia.

[0013] A fourth object of the present invention is to provide a medicine for treating and / or preventing hyperargininemia, wherein the medicine comprises the Bacillus licheniformis or the bacterial agent.

[0014] Furthermore, when the drug is used, the concentration of Bacillus licheniformis is 1×10 6 ~1×10 9 CFU / g of drug administration.

[0015] Furthermore, the medicine includes excipients, pharmaceutically acceptable media and carriers.

[0016] Furthermore, the medicine also includes one or more of a lubricant, a wetting agent, an emulsifier, a suspension stabilizer, a preservative, a sweetener, and a flavoring.

[0017] Furthermore, the dosage form of the drug is an enteric coating preparation.

[0018] The beneficial effects of the present invention are:

[0019] The Bacillus licheniformis provided by the present invention was deposited with the General Microbiology Center of the China Culture Collection Administration on April 14, 2023, at No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing, with the deposit number CGMCC No. 27112. The Bacillus licheniformis provided by the present invention can significantly reduce arginine levels and has the therapeutic potential to alleviate hyperargininemia. It can be used to prepare medicines or health products for the treatment and / or prevention of hyperargininemia.

[0020] Biomaterial Deposit

[0021] Bacillus licheniformis, taxonomically named Bacillus licheniformis, was deposited in the General Microbiology Center of the China Culture Collection Administration on April 14, 2023, with the deposit number CGMCC No. 27112, and the deposit address is No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing. Description of the drawings:

[0022] Figure 1 shows the growth of Bacillus licheniformis using Arg as the sole carbon source;

[0023] Figure 2 is a standard curve for determining Arg content by Sakaguchi reaction;

[0024] Figure 3 shows the degradation rate of Arg by Bacillus in the anaerobic intestinal fluid reaction system;

[0025] FIG4 shows the effect of nutrients on Arg degradation by Bacillus licheniformis;

[0026] Figure 5 shows exogenous 13 C-Arg arginine metabolism in mice;

[0027] Figure 6 shows the metabolism of endogenous Arg arginine in mice. DETAILED DESCRIPTION

[0028] The present invention will be further described below with reference to specific examples so that those skilled in the art can better understand the present invention and implement it, but the examples are not intended to limit the present invention.

[0029] After extensive and in-depth research and experiments, the inventors screened a strain of Bacillus licheniformis with potential therapeutic effects in preventing and treating hyperargininemia. The above-mentioned pure culture of Bacillus licheniformis was sequenced and identified by 16S rRNA sequencing. After comparison with the NCBI database Blast, it was identified as Bacillus licheniformis. The corresponding Chinese name is Bacillus licheniformis. The strain was deposited in the General Microbiology Center of the China Culture Collection of Microorganisms on April 14, 2023. The deposit address is No. 3, No. 1 Beichen West Road, Chaoyang District, Beijing. The strain deposit number is CGMCC No. 27112, and the strain is named USS-BLI-23001.

[0030] First, a series of in vitro experiments showed that the Bacillus licheniformis had outstanding arginine degradation and metabolic capabilities compared with other species of the genus Bacillus.

[0031] Secondly, the active bacterial agent containing Bacillus licheniformis was fed to the experimental subjects C57BL / 6J mice, and the mice were gavage 13 CL-Arg distinguishes between food-derived and endogenous amino acids. 13 C of CL-Arg in mice max value, and has the potential to treat and alleviate hyperarginineemia.

[0032] The present invention also provides use of the Bacillus licheniformis in treating hyperargininemia and other related diseases.

[0033] The bacterial agent of the present invention can be administered in the form of tablets, injections or capsules. The pharmaceutical preparation includes excipients, pharmaceutically acceptable media or carriers, which can be selected according to the route of administration. The pharmaceutical preparation of the present invention also includes auxiliary components.

[0034] Among them, lactose, glucose, sucrose, sorbitol, mannose, starch, gum arabic, calcium phosphate, alginate, gelatin, calcium silicate, fine crystalline cellulose, polyvinyl pyrrolidone (PVP), cellulose, water, syrup, methylcellulose, methyl hydroxybenzoate, propyl hydroxybenzoate, talc, magnesium stearate or mineral oil can be used as carriers, excipients or diluents of the medicine of the present invention.

[0035] In addition, the pharmaceutical inoculum of the present invention may further include lubricants, wetting agents, emulsifiers, suspending emulsion stabilizers, preservatives, sweeteners, and flavorings. The pharmaceutical inoculum of the present invention may be produced in an enteric coating formulation using various well-known methods to facilitate smooth passage of the active ingredient of the pharmaceutical composition, i.e., the microorganism, through the stomach without being destroyed by gastric acid.

[0036] The pharmaceutical preparation of the present invention can be made into enteric-coated tablets for oral use.

[0037] Unless otherwise specified, the experimental methods used in the following examples are conventional methods.

[0038] Unless otherwise specified, the materials and reagents used in the following examples can be obtained from commercial sources.

[0039] Example 1: Growth assay analysis using arginine as the sole carbon source

[0040] The experiment used arginine (Arg) as the sole carbon source to measure the growth of Bacillus licheniformis.

[0041] The above-mentioned Bacillus licheniformis strain was inoculated into liquid LB medium (10 g / L tryptone, 5 g / L yeast extract, and 10 g / L sodium chloride) and aerobically fermented at 37°C for 16 hours. After the cells were collected, they were washed twice with sterile 0.9% NaCl solution, added with sterile distilled water, resuspended, and incubated in a 37°C constant-temperature incubator for 48 hours to obtain a starvation bacterial suspension. Arginine mother liquor was sterilized by filtration using a 0.22 μm water filter and then added separately to the culture medium. The nitrogen-based basal medium was autoclaved at 121°C for 20 minutes. After cooling, the arginine mother liquor was added to the culture medium to bring the arginine concentration to 5 g / L. This culture medium was used as the arginine metabolism screening medium. The nitrogen-based culture medium contains 33.90 g / L Na2HPO4, 15.00 g / L KH2PO4, 2.50 g / L NaCl, and 5.00 g / L NH4Cl. 600 =1.0±0.1, inoculate into 100mL of liquid arginine metabolism screening medium at a ratio of 1%. Incubate at 37℃ in a shaker, take samples at intervals during the culture, and measure the OD value of the strain using a UV spectrophotometer. 600 The growth of the strain was recorded. The above-mentioned Bacillus licheniformis grew well in the culture medium with arginine as the sole carbon source, and the growth curve of the strain was plotted as shown in Figure 1.

[0042] Example 2: Genome Analysis and In Vitro Functional Analysis of Arginine Metabolism in Bacillus licheniformis

[0043] The strain tested was Bacillus licheniformis USS-BLI-23001 (abbreviated as BLI). Genome analysis of BLI revealed that the strain had functional genes related to arginine metabolism, such as arcA, speA, and arcR.

[0044] Detection method

[0045] A Sakaguchi test was established for the quantitative detection of Arg. The Sakaguchi test is a characteristic test for the detection of monosubstituted guanidines and is widely used for the analysis and determination of arginine. The experimental principle is the reaction of arginine with sodium hypochlorite and α-naphthol in an alkaline solution to produce a red product. The UV absorbance of various Arg concentrations was measured spectrophotometrically, and a standard curve was established to analyze the residual Arg content in the reaction system. The concentrations and volumes of the various Sakaguchi reaction systems are shown in Table 1.

[0046] Table 1 Sakaguchi reaction test Arg content components of each system

[0047] The Sakaguchi reaction was performed as follows: 400 μL of NaOH and 200 μL of α-naphthol were added to 2 mL of the sample to be tested at a specific dilution factor, the mixture was thoroughly vortexed, 30 μL of NaClO was added, the mixture was thoroughly vortexed, the reaction was allowed to react at room temperature for 1 min, and 400 μL of urea was added to terminate the reaction. After vortexing, 200 μL of each sample was aliquoted for measurement, and the absorbance was measured at 495 nm using a microplate reader (Hangzhou Aosheng FlexA-200).

[0048] Drawing of the standard curve of arginine (Arg)

[0049] The concentration gradient of Arg standard solution was 0.01g / L; 0.025g / L; 0.035g / L; 0.05g / L; 0.075g / L. The absorbance at 495nm was tested by Sakaguchi reaction. 495 A standard curve was made with the concentration of Arg, as shown in Figure 2.

[0050] The experiment tested the in vitro degradation efficiency of Arg by different strains of Bacillus:

[0051] In addition to digestion in the stomach, foreign bacterial strains must undergo digestion and transport in the small intestine to reach their destination and function. Therefore, this study used artificial intestinal fluid as the reaction system, and simultaneously measured and analyzed the strains' tolerance to intestinal fluid. The artificial intestinal fluid used in this experiment was SL6610 artificial intestinal fluid (sterilized, containing enzymes) from Beijing Coolable Technology Co., Ltd. (Coolaber). The reagents were sterile, consisting primarily of potassium dihydrogen phosphate and pancreatic enzymes, as described in the Chinese Pharmacopoeia.

[0052] The strains used in the experiment are: Bacillus licheniformis is a deposited strain of this patent with a deposit number of CGMCC No. 27112, Bacillus subtilis was purchased from the China General Culture Collection of Microorganisms with a strain number of CGMCC No. 1.9086, Bacillus cereus was purchased from the China General Culture Collection of Microorganisms with a strain number of CGMCC No. 1.9067, Bacillus amyloliquefaciens was purchased from the China General Culture Collection of Microorganisms with a strain number of CGMCC No. 1.10901, and Bacillus coagulans was purchased from the China General Culture Collection of Microorganisms with a strain number of CGMCC No. 1.10.

[0053] The culture medium used was LB medium (tryptone 10 g / L; yeast extract 5 g / L; sodium chloride 10 g / L). After fermentation at 37°C for 16 h, the cells were collected, washed and resuspended with sterile saline. The OD value of the bacterial solution was measured using a UV spectrophotometer. 600 (The bacterial concentration OD in this experiment 600 All were measured using an ultraviolet spectrophotometer (Unico UV-2365), which will not be repeated in the following text). The bacterial concentration of each strain was adjusted to OD 600 =2.0, corresponding to a bacterial count of 10 9 CFU / ml. The reaction system was artificial intestinal fluid. Arg was added to the reaction system to a concentration of 0.2 g / L (1.1 mM). The reaction was allowed to stand at 37°C under anaerobic conditions. Samples were taken after 1 and 2 hours of reaction to determine the remaining Arg content in the reaction system. The Arg degradation rate of the strain was calculated. The experimental results are shown in Figure 3.

[0054] The experiment tested the in vitro inhibitory effect of different nutrients on the degradation of Arg by Bacillus licheniformis:

[0055] Materials: Glucose (Cat. No.: 2106011) was purchased from Xilong Scientific Co., Ltd., tryptone (Cat. No.: 3256061) was purchased from OXOID, and casein hydrolysate (Cat. No.: A603080-0100) was purchased from Shanghai Sangon Co., Ltd.

[0056] Methods: The strain enters the human body orally and exerts its effects in the human intestine. Due to the complex nutritional components in the human intestine, the strain may affect the degradation of Arg. In order to verify whether complex nutritional components will inhibit the strain from degrading Arg, the experiment was designed to add glucose (G), trypsin (Typ) and casein hydrolysate (Ltm) to the original Arg reaction system to compare the degradation of Arg. The Arg concentration of the reaction system was set to 0.2g / L, and the added concentrations of G, Typ and Ltm were 5g / L. The bacterial concentration of the reaction system was adjusted to OD 600 =2.0, and the reaction was allowed to stand at 37°C without oxygen for 1 hour. The experimental results are shown in Figure 4.

[0057] Example 3: Animal Experiment Verification

[0058] Material:

[0059] The tested strain is Bacillus licheniformis USS-BLI-23001 (abbreviated as BLI).

[0060] The concentration of BLI bacteria for oral administration was 2×10 10 CFU / ml. BLI inoculum for intragastric administration was frozen culture medium. The inoculum buffer (abbreviated as BLI-f) consisted of 15% glycerol, KH2PO4, K2HPO4, and pH adjusted to 7.5. Before intragastric administration, the frozen BLI culture medium was thawed in a 37°C water bath and thoroughly suspended.

[0061] C57BL / 6J mice were purchased from Beijing Weitonglihua Experimental Animal Co., Ltd. and housed at a temperature of 20-26°C, a constant humidity of 40-70%, a light intensity of 12 hours (07:00-19:00), soundproofing, free access to food and water, and experiments were performed after one week of acclimatization.

[0062] Stable isotope labeling 13 C-Arg arginine (catalog number MBBB4331V) was purchased from Sigma.

[0063] method:

[0064] Twenty-four female C57BL / 6J mice, 6-8 weeks old and weighing 18-20 g, were divided into three groups for the experiment.

[0065] (1) Blank group: 8 female C57BL / 6J mice, 6-8 weeks old, weighing 18-20 g,13 The oral administration volume of C-Arg was 10 μl / g, and the oral administration dose was 15 mpk;

[0066] (2) Experimental group: 8 female C57BL / 6J mice, 6-8 weeks old, weighing 18-20 g. 13 C-Arg gavage volume was 5 μl / g, gavage dose was 15 mpk; BLI gavage volume was 5 μl / g, gavage BLI agent first and then gavage 13 C-Arg.

[0067] (3) Control group: 8 female C57BL / 6J mice, 6-8 weeks old, weighing 18-20 g. 13 C-Arg was administered orally in a volume of 5 μl / g, with a dose of 15 mpk. BLI-f was administered orally in a volume of 5 μl / g, with BLI-f administered orally first and then administered orally. 13 C-Arg.

[0068] Bacteria and 13 After intragastric administration of C-Arg, blood samples were collected at 5, 10, 30, and 60 minutes, and exogenous C-Arg in the blood was detected by LC-MS. 13 C-Arg and endogenous Arg content were measured, and mice were anesthetized and killed after the last sampling.

[0069] Results: Compared with the blank group and the control group, the BLI strain could significantly reduce the exogenous 13 The content of C-Arg can be used to 13 C-Arg C max The results were shown in FIG5 , and there was no significant effect on endogenous Arg, as shown in FIG6 .

[0070] The above embodiments are merely preferred embodiments for the purpose of fully illustrating the present invention, and the scope of protection of the present invention is not limited thereto. Equivalent substitutions or modifications made by those skilled in the art based on the present invention are within the scope of protection of the present invention. The scope of protection of the present invention shall be subject to the claims.

Claims

1. A strain of Bacillus licheniformis that degrades arginine, characterized in that: The Bacillus licheniformis was deposited in the General Microbiology Center of the China Culture Collection Administration on April 14, 2023, with the deposit number CGMCC No. 27112, and the deposit address is No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing.

2. A bacterial agent comprising the Bacillus licheniformis according to claim 1.

3. The bacterial agent according to claim 2, characterized in that: The bacterial agent is prepared by the following method: The Bacillus licheniformis strain is inoculated into a culture medium for cultivation, the bacterial bodies are collected after cultivation, and the collected bacterial bodies are prepared into the bacterial agent.

4. The bacterial agent according to claim 2, characterized in that: The bacterial agent is a liquid bacterial agent or a solid bacterial agent.

5. Use of the Bacillus licheniformis according to claim 1 or the bacterial agent according to any one of claims 2 to 4 in the preparation of medicines or health products for treating and / or preventing hyperargininemia.

6. A drug for treating and / or preventing hyperargininemia, characterized in that: The medicine contains the Bacillus licheniformis according to claim 1 or the bacterial agent according to any one of claims 2 to 4.

7. The medicine according to claim 6, characterized in that: The concentration of Bacillus licheniformis in the drug is 1×10 6 ~1×10 9 CFU / g.

8. The medicine according to claim 6, characterized in that: The drug includes excipients, pharmaceutically acceptable media or carriers.

9. The medicine according to claim 8, characterized in that: The medicine also includes one or more of a lubricant, a wetting agent, an emulsifier, a suspension stabilizer, a preservative, a sweetener, and a flavor.

10. The medicine according to claim 6, characterized in that: The dosage form of the drug is an enteric coating preparation.

Citation Information

Patent Citations

  • Bacillus licheniformis and application thereof in degradation of beta-cypermethrin

    CN104560836A

  • Novel Bacillus licheniformis strain and application thereof

    CN106190929A

  • Bacillus licheniformis and application of bacillus licheniformis in constipation prevention and treatment

    CN109402030A

  • Bacillus licheniformis for degrading arginine and application of bacillus licheniformis

    CN116355815A

  • Bacillus licheniformis strain KJ-10 and uses thereof

    KR1020160144630A